Roivant Sciences Ltd. 4

Director Meghan Fitzgerald had 1,743 Roivant Sciences Ltd. common shares withheld in a tax-related net settlement tied to equity compensation vesting, leaving her with 41,220 shares owned directly.

On September 10, 2026, Roivant Sciences Ltd. director Meghan Fitzgerald had 1,743 common shares withheld by the company at an implied price of $40.94 per share in a net-share settlement to cover tax withholding obligations related to the vesting and settlement of previously granted director compensation shares, reducing her directly held position to 41,220 common shares after the transaction. Because this was a routine tax withholding event tied to equity compensation rather than an open‑market purchase or discretionary sale, it is best viewed as administrative in nature and not as a directional trading signal.

Filing Facts

CIK

1635088

Ticker

ROIV

Form

4

Source Type

fda

Accession

0001349297-26-000006

Alert Tier

4